What kind of drug does evantuzumab belong to?

Amivantamab (amivantamab) is an innovative biopharmaceutical. Specifically, it belongs to the monoclonal antibody class. As an EGFR/cMET bispecific antibody, evantumumab combines the therapeutic mechanisms of two targets and aims to provide more effective treatment options for patients with specific types of non-small cell lung cancer (NSCLC).

First of all, to understand the classification of evantumumab, we need to start with its structure and function. Monoclonal antibodies are produced through immunological technology and are designed and produced to target specific antigens. Evantumumab specifically targets the epidermal growth factor receptor (EGFR) and c-MET receptors, which play key roles in the development and progression of a variety of tumors. EGFR is a protein expressed on the surface of many tumor cells, and its mutations often lead to uncontrolled cell proliferation, thereby causing tumors. The c-MET receptor is closely related to cell migration, invasion and metastasis. In non-small cell lung cancer, EGFR exon 20 insertion mutation is an important biomarker and is closely related to the malignancy and prognosis of the disease.

Evantumumab achieves dual inhibition of tumor growth signaling by targeting both receptors simultaneously. The innovative nature of its mechanism enables it to demonstrate good clinical efficacy in the treatment of specific patients with advanced or metastatic non-small cell lung cancer. This bispecific design enables evantumumab to effectively deal with drug resistance issues that may arise in tumor cells during treatment, further improving the therapeutic effect.

In clinical trials, evantumumab has been shown to improve survival and quality of life, especially in patients who have failed other standard treatments. Due to its unique mechanism of action and good clinical performance, evantumumab was approved by the FDA in 2021 and received marketing authorization from the European Union in the same year, becoming an important breakthrough in this field.

Reference materials:https://www.rybrevant.com/